Faculty profile

Anna Spreafico

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Anna Spreafico

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
99 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

167

Publications

290

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Oral And Intestinal Microbiome Profiling

Latest papers

Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.
Oral oncology · 2026
Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
Genetically Proxied Inhibition of Cholesterol-Lowering Drug Targets and Survival in HPV-Positive and Non-HPV-Driven Head and Neck Cancer: A Multicentre MR Study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026

All 167 publications

Latest funding

Prognostic Biomarkers and Novel Therapies for Oral Squamous Cell Carcinoma Patients
CIHR · 2019 · Co-investigator
$1,051,875
A multi institutional study evaluating the role of the gut microbiome on immune checkpoint inhibitor efficacy and toxicity in advanced solid tumors
CIHR · 2018 · Co-investigator
$25,000
Genomics-based radiosensitization for HPV-negative squamous cell carcinoma of the aerodigestive tract
CIHR · 2018 · Co-investigator
$757,352

All 4 grants and awards

From the 150 most recent of 167 publications.

Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.

Alsulami S, Rühle A, Yu E, Su J, O'Sullivan B, Hosni A, Waldron JN, Weinreb I, Smith S, de Almeida J, Goldstein D, Yao CM, McPartlin A, Bayley A, Bratman SV, Hahn E, Hope A, Kim J, Malik N, Sanz-Garcia E, Spreafico A, Tong L, Xu W, Bartlett E, Huang SH

Oral oncology2026

DOI: 10.1016/j.oraloncology.2026.108140 PMID: 42732755

Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.

Rühle A, Sanz-Garcia E, Su J, O'Sullivan B, Waldron JN, Spreafico A, Siu L, Eng L, McPartlin A, Bayley A, Bratman SV, Hahn E, Hope A, Hosni A, Malik N, Tsai J, de Almeida J, Xu W, Kim J, Huang SH

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026

DOI: 10.1016/j.radonc.2026.111769 PMID: 42697275

Genetically Proxied Inhibition of Cholesterol-Lowering Drug Targets and Survival in HPV-Positive and Non-HPV-Driven Head and Neck Cancer: A Multicentre MR Study.

Cheng D, Hueniken K, Hou T, Shu T, Espin-Garcia O, Dudding T, Gormley M, McKay JD, de Almeida JR, Hope AJ, Spreafico A, Huang SH, Schroeder L, Waterboer T, Hayes DN, Virani S, Brennan P, Pring M, Olshan AF, Diergaarde B, Macfarlane GJ, Lagiou P, Lagiou A, Polesel J, Agudo A, Alemany L, Ahrens W, Healy CM, Conway DI, Canova C, Holcatova I, Ren J, Zhao Y, Hung RJ, Mondul AM, Xu W, Liu G

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026

DOI: 10.1158/1055-9965.epi-26-0066 PMID: 42390334

Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?

Lopes CDH, Spreafico A, Araujo DV

Translational cancer research2026

DOI: 10.21037/tcr-2026-1245 PMID: 42724840

Time-dependent analysis of HUS change in older patients aged > 75 years with head and neck cancer.

Cheng D, Hueniken K, Hope A, Huang SH, Spreafico A, Goldstein DP, Bratman SV, Zhao Y, Ren J, de Almeida JR, Xu W, Liu G

Health and quality of life outcomes2026

DOI: 10.1186/s12955-026-02551-7 PMID: 42608688

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Herrera M, Marhon SA, Liu ZA, Loo H, Abbas-Aghababazadeh F, Bruce JP, Chen D, Van de Laar E, Chow H, Bedard PL, Abdul Razak AR, Spreafico A, Butler MO, Lheureux S, Pugh TJ, Haibe-Kains B, Siu LL, De Carvalho DD, Spiliopoulou P

Cancer immunology research2026

DOI: 10.1158/2326-6066.cir-26-0365 PMID: 42593482

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Gaspar C, Wu B, Stone SC, Sotov V, Wang B, Wangulu C, Berman H, Kay A, Basra P, Van de Laar E, Bratman S, Lheureux S, Knox J, Kim R, He H, Liu G, Bedard P, Spreafico A, Tsao M, Pugh TJ, Hansen A, Sapisochin G, Garcia ES, Siu LL, Bruce JP

Frontiers in oncology2026

DOI: 10.3389/fonc.2026.1876853 PMID: 42625601

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer.

Chelvarajah RC, Chee LYS, Su J, O'Sullivan B, Yao CMKL, Sanz-Garcia E, Smith SM, Weinreb I, Bratman S, Cho BCJ, Hahn E, Hope A, Hosni A, Kim J, McPartlin A, Malik N, Tsai CJ, de Almeida J, Spreafico A, Tong L, Huang SH, Waldron JN

Head & neck2026

DOI: 10.1002/hed.70230 PMID: 41816946

Practices and Impressions of Head and Neck Cancer Multidisciplinary Tumor Boards Findings From an American Head and Neck Society Survey.

Yao CMKL, Beatty S, Yan F, Esemezie AO, Huang SH, Tam S, Misfud M, Hosni A, Hahn E, Spreafico A, Al-Sajee D, Yu E, Monteiro E, Goldstein DP, de Almeida JR, Gilbert RW, Sturgis EM, Ridge JA, Galloway TJ

Head & neck2026

DOI: 10.1002/hed.70228 PMID: 41813226

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial.

Icht O, Sun A, Wong P, McPartlin A, Muniz TP, Spreafico A, Saibil SD, Lukens JN, Karam SD, De Almeida J, Butler MO, Tsai CJ

Frontiers in oncology2026

DOI: 10.3389/fonc.2026.1841070 PMID: 42518820

Something wrong or missing on this profile? Suggest a correction

Anna Spreafico

Research

Latest papers

Latest funding

Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.

Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.

Genetically Proxied Inhibition of Cholesterol-Lowering Drug Targets and Survival in HPV-Positive and Non-HPV-Driven Head and Neck Cancer: A Multicentre MR Study.

Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?

Time-dependent analysis of HUS change in older patients aged&#x2009;>&#x2009;75 years with head and neck cancer.

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer.

Practices and Impressions of Head and Neck Cancer Multidisciplinary Tumor Boards Findings From an American Head and Neck Society Survey.

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) -&#xa0;a single arm, phase 2 clinical trial.

Prognostic Biomarkers and Novel Therapies for Oral Squamous Cell Carcinoma Patients

A multi institutional study evaluating the role of the gut microbiome on immune checkpoint inhibitor efficacy and toxicity in advanced solid tumors

Genomics-based radiosensitization for HPV-negative squamous cell carcinoma of the aerodigestive tract

Oral and intestinal microbiome profiling in intermediate risk locally advanced head and neck squamous cell carcinoma patients receiving chemoradiotherapy and immunoradiotherapy

Frequent collaborators

Wei Xu

Andrew Hope

John Kim

John de Almeida

Meredith Giuliani

Enrique Sanz Garcia

Stephanie Lheureux

Geoffrey Liu

Lisa Wang

Scott Bratman

Bryan Coburn

Lawson Eng

Benjamin Haibe-Kains

Ian Witterick

Lisa Avery

Lillian Siu

Sareh Keshavarzi

Jonathan Irish

Christopher Yao

Emma Allen-Vercoe

Philip Wong

Michael Ong

Michael Glogauer

Naoto Hirano

Sebastien Hotte

Osvaldo Espin Garcia

Marcus Butler

Adrian Sacher

Neesha Dhani

Fei-Fei Liu

Andrzej Chruscinski

Catalin Mihalcioiu

Rupert Kaul

Catherine O'Brien

Kelvin Chan

Marcelo Cypel

Anna Goldenberg

Rosemary Martino

Andrea Benedetti

Srikala Sridhar

Time-dependent analysis of HUS change in older patients aged > 75 years with head and neck cancer.

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial.